Phaseline

Companies › Nanjing IASO Biotechnology

Nanjing IASO Biotechnology: clinical trials, targets and expected readouts

4 active drug programs in 4 registered trials: 3 Phase 1, 1 Phase 3; Oncology, Immunology; next expected readout Aug 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Equecabtagene Autoleucel Injection
CAR-T cell therapy targeting CD138 and/or BCMA
–Phase 3Multiple MyelomaAug 2027
UB-VV410
CD19-targeted CAR-T cell therapy
–Phase 1Systemic Lupus ErythematosusMay 2028
UB-VV400
Third-generation self-inactivating lentiviral vector encoding anti-CD19 CAR-T cells
–Phase 1Large B-cell LymphomaMay 2028
CAR-GPRC5D (RD118)
anti-GPRC5D CAR-T cell therapy
GPRC5DPhase 1Relapsed/Refractory Multiple Myeloma–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05759793CAR-GPRC5D (RD118)Phase 1Relapsed/Refractory Multiple MyelomaOncologySep 2025
NCT06464991Equecabtagene Autoleucel InjectionPhase 3Multiple MyelomaOncologyAug 2027
NCT07109986UB-VV410Phase 1Systemic Lupus ErythematosusImmunologyMay 2028
NCT06743503UB-VV400Phase 1Large B-cell LymphomaOncologyMay 2028

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

GPRC5D (1)

Companies with the same targets

Johnson & Johnson (Janssen) Regeneron Pharmaceuticals Bristol-Myers Squibb O&D BioTech Group OriCell Therapeutics Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Bayer

Companies built like this

PharmaMar GI Innovation Nanjing Leads Biolabs Chipscreen Biosciences RayzeBio

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.